Factor D complement inhibitors companies working in the market are AstraZeneca, Alexion (a subsidiary of AstraZeneca), BioCryst, and others. ALBANY, NY, UNITED STATES, December 4, 2024 /EINPresswire / ...

BioCryst Pharmaceuticals, Inc. proof-of-concept data from a phase 1 study, using BCX10013 for the treatment of patients with complement-mediated disorders, is expected in 2024. Oral C2, C5, and ...

Achillion Pharmaceuticals, Inc.ACHN announced positive interim data from clinical studies evaluating its factor D inhibitors - ACH-4471, ACH-5228 and ACH-5548. Two phase II studies are evaluating the ...

The first-in-class oral factor D inhibitor danicopan (Voydeya) has been approved for the management of extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). EVH affects ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), ...